DR. LELAND GERSHELL, M.D., PH.D.
Osteopathic Medicine at 77 St, New York, NY
License number
New York 230701
Category
Osteopathic Medicine
Type
General Practice
Address
Address
201 E 77Th St APT 9F, New York, NY 10075
Phone
(212) 737-6154
Personal information
See more information about LELAND GERSHELL at radaris.comName
Address
Phone
170 E 87Th St APT W15A, New York, NY 10128
55 W 26Th St APT 10D, New York, NY 10010
New York, NY
55 26Th St, New York, NY 10010
600 111Th St, New York, NY 10025
Organization information
See more information about LELAND GERSHELL at bizstanding.comLeland Gershell MD,PHD
170 E 87 St Apt W15A, New York, NY 10128
Industry:
Family Doctor
Phone:
(212) 737-6154 (Phone)
Leland James Gershell
Professional information
See more information about LELAND GERSHELL at trustoria.com
Leland Gershell
Leland Gershell
Position:
Chief Financial Officer at TONIX Pharmaceuticals
Location:
New York, New York
Industry:
Pharmaceuticals
Work:
TONIX Pharmaceuticals
- New York, NY since Apr 2012
-
Chief Financial Officer
Madison Williams and Company
May 2011 - Apr 2012
-
Managing Director
Apothecary Capital LLC
Oct 2008 - Oct 2009
-
Senior Analyst
Cowen and Company
Nov 2004 - Sep 2008
-
Equity Analyst - Biotechnology
Education:
Columbia University College of Physicians and Surgeons 1994 - 2002
Columbia University in the City of New York 1996 - 2000
Dartmouth College 1990 - 1994
Stuyvesant High School 1986 - 1990
Collegiate School 1978 - 1986
Columbia University in the City of New York 1996 - 2000
Dartmouth College 1990 - 1994
Stuyvesant High School 1986 - 1990
Collegiate School 1978 - 1986
Dr. Leland Gershell, New York NY - MD (Doctor of Medicine)
Dr. Leland Gershell, New York NY - MD (Doctor of Medicine)
Specialties:
Family Medicine
Address:
201 E 77Th St SUITE 9F, New York 10075
(212) 737-6154 (Phone)
(212) 737-6154 (Phone)
Languages:
English
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1998
Columbia University / College of Physicians And Surgeons
Graduated: 1998
Class Of Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
Class Of Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
US Patent:
6511990, Jan 28, 2003
Filed:
Aug 24, 2000
Appl. No.:
09/645430
Inventors:
Ronald Breslow - Englewood NJ
Sandro Belvedere - New York NY
Leland Gershell - New York NY
Thomas A. Miller - New York NY
Paul A. Marks - Washington CT
Victoria M. Richon - New York NY
Richard A. Rifkind - New York NY
Sandro Belvedere - New York NY
Leland Gershell - New York NY
Thomas A. Miller - New York NY
Paul A. Marks - Washington CT
Victoria M. Richon - New York NY
Richard A. Rifkind - New York NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
The Trustees of Columbia University in the City of New York - New York NY
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K 314709
US Classification:
514314, 514249, 514261, 514266, 514307, 514309, 514311, 514316, 514318, 514354, 514355, 514575, 544277, 544258, 546171, 546141, 546146, 546314, 546316, 562623, 562622
Abstract:
The present invention provides the compound having the formula: wherein each of R and R is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, âOâ, âSâ, âNHâ, or âCH â; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
Novel Class Of Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
Novel Class Of Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
US Patent:
2007001, Jan 11, 2007
Filed:
Jun 22, 2006
Appl. No.:
11/474042
Inventors:
Ronald Breslow - Englewood NJ, US
Sandro Belvedere - New York NY, US
Leland Gershell - New York NY, US
Thomas Miller - New York NY, US
Paul Marks - Washington CT, US
Victoria Richon - New York NY, US
Richard Rifkind - New York NY, US
Sandro Belvedere - New York NY, US
Leland Gershell - New York NY, US
Thomas Miller - New York NY, US
Paul Marks - Washington CT, US
Victoria Richon - New York NY, US
Richard Rifkind - New York NY, US
International Classification:
C07D 473/02, C07D 211/06, C07C 259/04, C07D 213/56
US Classification:
544277000, 546226000, 562621000, 562623000, 546336000, 548190000
Abstract:
The present invention provides the compound having the formula:
wherein each of Rand Ris, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
Novel Class Of Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
Novel Class Of Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
US Patent:
2007001, Jan 11, 2007
Filed:
Jun 22, 2006
Appl. No.:
11/473839
Inventors:
Ronald Breslow - Englewood NJ, US
Sandro Belvedere - New York NY, US
Leland Gershell - New York NY, US
Thomas Miller - New York NY, US
Paul Marks - Washington CT, US
Victoria Richon - New York NY, US
Richard Rifkind - New York NY, US
Sandro Belvedere - New York NY, US
Leland Gershell - New York NY, US
Thomas Miller - New York NY, US
Paul Marks - Washington CT, US
Victoria Richon - New York NY, US
Richard Rifkind - New York NY, US
International Classification:
A61K 31/52, A61K 31/445, A61K 31/44, C07C 259/04
US Classification:
514263400, 514317000, 514370000, 514357000, 514575000, 544277000, 546226000, 546304000, 562621000, 562623000
Abstract:
The present invention provides the compound having the formula:
wherein each of Rand Ris, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.
Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
US Patent:
7345174, Mar 18, 2008
Filed:
Jun 22, 2006
Appl. No.:
11/474043
Inventors:
Ronald Breslow - Englewood NJ, US
Sandro Belvedere - New York NY, US
Leland Gershell - New York NY, US
Thomas A. Miller - New York NY, US
Paul A. Marks - Washington CT, US
Victoria M. Richon - New York NY, US
Richard A. Rifkind - New York NY, US
Sandro Belvedere - New York NY, US
Leland Gershell - New York NY, US
Thomas A. Miller - New York NY, US
Paul A. Marks - Washington CT, US
Victoria M. Richon - New York NY, US
Richard A. Rifkind - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
The Trustees of Columbia University in the City of New York - New York NY
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
C07D 221/02, C07D 211/00, C07D 211/60, C07C 233/60, A61K 31/02, A61K 31/12, A61K 31/22
US Classification:
546112, 546184, 546192, 546245, 546 90, 564123, 514183, 514506, 514675, 514759, 544 56, 544256
Abstract:
The present invention provides the compound having the formula:.
Class Of Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
Class Of Cytodifferentiating Agents And Histone Deacetylase Inhibitors, And Methods Of Use Thereof
US Patent:
7126001, Oct 24, 2006
Filed:
Oct 25, 2002
Appl. No.:
10/281875
Inventors:
Ronald Breslow - Englewood NJ, US
Sandro Belvedere - New York NY, US
Leland Gershell - New York NY, US
Thomas A. Miller - New York NY, US
Paul A. Marks - Washington CT, US
Victoria M. Richon - New York NY, US
Richard A. Rifkind - New York NY, US
Sandro Belvedere - New York NY, US
Leland Gershell - New York NY, US
Thomas A. Miller - New York NY, US
Paul A. Marks - Washington CT, US
Victoria M. Richon - New York NY, US
Richard A. Rifkind - New York NY, US
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
The Trustees of Columbia University in the City of New York - New York NY
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
C07D 215/38, C07D 473/02, C07C 259/04, A61K 31/47
US Classification:
546171, 546141, 546146, 546314, 546315, 544277, 544258, 562622, 562623, 514314, 514249, 514261, 514268, 514307
Abstract:
The present invention provides the compound having the formula:.